CKD Progression Prediction via Biomarker Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical practices lack effective tools for identifying individuals with chronic kidney disease (CKD) at high risk of progression, making it challenging to tailor therapy and predict disease outcomes, which hinders the development of novel therapeutic approaches.
Innovation Solution
A method involving the detection of biomarkers such as GDF-15, EGF, NT-proBNP, ApoH, and albumin to creatinine ratio (AUCR) in patient samples, comparing their levels to reference amounts to identify subjects at increased risk of CKD progression, allowing for personalized treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional clinical practices are used for CKD management, then general treatment approaches are applied, but the ability to identify high-risk patients for personalized therapy is lost
Solution Approach 1:
The patent segments the heterogeneous CKD patient population into distinct risk groups (high-risk and low-risk) based on biomarker profiles. This segmentation enables personalized treatment strategies by identifying specific subsets of patients who would benefit most from intensive therapy or novel interventions, rather than applying uniform treatment to all CKD patients.
Solution Approach 2:
The patent performs preliminary risk stratification using biomarker detection (GDF-15, EGF, NT-proBNP, ApoH, AUCR) before initiating or intensifying therapy. This preliminary action allows clinicians to identify high-risk patients early, enabling proactive personalized treatment planning and avoiding unnecessary interventions in low-risk patients.
2Measurement precision
If biomarker detection methods are implemented, then early identification of high-risk patients is achieved, but the complexity of clinical testing increases
Solution Approach 1:
The patent employs a multi-functional biomarker panel where five different biomarkers (GDF-15, EGF, NT-proBNP, ApoH, and AUCR) collectively provide comprehensive risk assessment. This universal approach allows a single testing protocol to capture multiple aspects of disease progression risk, improving measurement precision while consolidating what could otherwise be multiple separate tests.
Solution Approach 2:
The patent uses biomarker levels as surrogate copies or proxies for the complex underlying pathological processes driving CKD progression. Instead of directly measuring disease progression (which would require complex longitudinal monitoring), the biomarkers serve as measurable copies that correlate with progression risk, simplifying the assessment while maintaining predictive accuracy.
3Reliability
If intensive monitoring and therapy are applied to all CKD patients, then treatment efficacy may be improved, but unnecessary interventions are performed on low-risk patients
Solution Approach 1:
The patent applies local quality by tailoring the intensity of monitoring and therapy to the specific risk profile of each patient group. High-risk patients identified through biomarker elevation receive intensive monitoring and novel therapeutic interventions, while low-risk patients receive standard care. This localized approach optimizes treatment efficacy for those who need it most while avoiding harmful unnecessary interventions in low-risk patients.
Solution Approach 2:
The patent takes preliminary anti-action by identifying and flagging high-risk patients before disease progression occurs. Through early biomarker detection, the system preemptively counteracts the risk of progression by enabling timely intensification of therapy, while simultaneously preventing the harmful effect of unnecessary intensive therapy in low-risk patients who would not benefit from such interventions.
Data Source
AI summary
Subject of the present invention are biomarkers and methods for the identification of an increased risk of the progression of chronic kidney disease (CKD), or for monitoring chronic kidney disease therapy, comprising the detecting the level of one or more of NTpro BNP, EGF, Apo H, GDF-15, and albumin-to-creatinine ratio.